OCD FAQs — 50 Most-Asked Questions, Backed by Peer-Reviewed Science

OCD FAQs — 50 Most-Asked Questions, Backed by Peer-Reviewed Science

Welcome. This evidence-based guide answers the 50 most common questions about Obsessive-Compulsive Disorder (OCD), drawn from peer-reviewed psychiatry, clinical psychology, and neuroscience research. Citations include DSM-5-TR, ICD-11, NICE CG31, the International OCD Foundation (IOCDF), Cochrane systematic reviews, and leading OCD researchers including Edna Foa, Jonathan Abramowitz, Stanley Rachman, Paul Salkovskis, David Clark, James Leckman, Jon Grant, Reid Wilson, and Steven Phillipson.

Numbered citations link to the reference list at the end of the page. This guide is educational and does not replace personalized assessment by a licensed clinician.

If you are in crisis or having thoughts of suicide: In the U.S. & Canada, call or text 988 (Suicide & Crisis Lifeline). Many people with OCD experience disturbing intrusive thoughts about self-harm — these are typically OCD symptoms, not genuine suicidal intent, but if you are uncertain, please reach out for support. Kids Help Phone Canada: 1-800-668-6868. If life is in immediate danger, call 911.
Jump to a section:
1. Understanding OCD 2. Symptoms & Themes 3. Diagnosis 4. Treatment 5. Living with OCD 📚 References

Section 1 — Understanding OCD

1. What is OCD? (DSM-5-TR definition)

Obsessive-Compulsive Disorder (OCD) is a chronic, often disabling neuropsychiatric condition characterized by the presence of obsessions (recurrent, unwanted, intrusive thoughts, images, or urges that cause marked anxiety or distress) and/or compulsions (repetitive behaviours or mental acts the person feels driven to perform to reduce that distress)1,2. To meet DSM-5-TR criteria, these symptoms must be time-consuming (>1 hour/day) or cause clinically significant distress or impairment, and not be better explained by another condition1. The ICD-11 places OCD in its own diagnostic group, Obsessive-Compulsive and Related Disorders3.

2. What’s the difference between obsessions and compulsions?

Obsessions are internal events: intrusive thoughts, images, urges, or sensations that arrive uninvited and feel ego-dystonic (against the person’s values)1,4. Compulsions are responses — overt behaviours (washing, checking) or covert mental acts (counting, praying, mental reviewing, reassurance-seeking) — performed to neutralize the obsession or prevent a feared outcome1,5. The compulsion provides short-term relief but reinforces the cycle, strengthening the obsession over time5,6.

3. What are the most common OCD subtypes/themes?

Factor-analytic studies (Bloch et al., 2008; Mataix-Cols et al., 2005) consistently identify four to five symptom dimensions: (1) contamination/cleaning, (2) symmetry/ordering/”just right”, (3) forbidden/taboo thoughts (harm, sexual, religious), (4) checking/responsibility for harm, and sometimes (5) hoarding (now usually classified separately)7,8. Most people have multiple themes; themes can shift over time8,9.

4. What causes OCD? (genetics, brain, environment)

OCD has a multifactorial etiology. Twin and family studies estimate heritability of 27-65%, higher in pediatric-onset cases10,11. Neuroimaging implicates the cortico-striato-thalamo-cortical (CSTC) circuit — particularly the orbitofrontal cortex, anterior cingulate cortex, caudate, and thalamus12,13. Neurochemically, serotonin and glutamate systems are implicated14,15. Environmental contributors include early stressors, trauma, infections (PANDAS/PANS), and learned cognitive patterns (inflated responsibility, thought-action fusion)16,17.

5. Is OCD a brain disorder or a learned behaviour?

Both. OCD has clear neurobiological correlates (hyperactivity in the CSTC loop, normalized after successful treatment with either ERP or SSRIs)13,18, and it is also maintained by learned behavioural and cognitive patterns — most importantly, the negative-reinforcement cycle in which compulsions reduce anxiety and thereby strengthen the obsession5,6. Effective treatment typically requires changing the behaviour (ERP) and/or modulating the neurochemistry (SSRIs)19,20.

6. How common is OCD? Who gets it?

The lifetime prevalence of OCD is approximately 2-3% worldwide; 12-month prevalence is around 1.2%21,22. OCD has a bimodal age of onset: one peak in childhood (ages 8-12, more common in boys) and another in late adolescence/early adulthood (ages 18-25, equal sex ratio or slight female predominance)23,24. The WHO ranks OCD among the top 20 causes of illness-related disability worldwide25.

7. Is OCD a form of anxiety disorder?

Historically, OCD was classified as an anxiety disorder. In DSM-5 (2013) and ICD-11 (2022), OCD was moved into its own category — Obsessive-Compulsive and Related Disorders — alongside body dysmorphic disorder, hoarding disorder, trichotillomania, and excoriation disorder1,3. Anxiety is a prominent symptom but not the defining one; disgust, “not just right” feelings, and incompleteness can also drive compulsions26,27.

8. What’s the difference between OCD and OCPD?

OCD (Obsessive-Compulsive Disorder) involves unwanted, ego-dystonic obsessions and compulsions that cause distress. OCPD (Obsessive-Compulsive Personality Disorder) is an enduring personality style of perfectionism, rigidity, control, and orderliness that is generally ego-syntonic — the person sees their traits as correct, not problematic1,28. The two can co-occur (~25-30%), but they are distinct conditions with different treatments28,29.

9. Can OCD develop suddenly in adults? (PANDAS/PANS)

Sudden, acute-onset OCD in children following streptococcal infection is recognized as PANDAS (Pediatric Autoimmune Neuropsychiatric Disorders Associated with Streptococcal infections) and the broader category PANS (Pediatric Acute-onset Neuropsychiatric Syndrome)30,31. In adults, sudden-onset OCD is rare but reported following infections, autoimmune events (including post-COVID), brain injury, or stroke affecting the basal ganglia32,33. New, abrupt OCD warrants medical evaluation.

10. Is OCD genetic or hereditary?

OCD aggregates in families. First-degree relatives of someone with OCD have a 4-9× increased risk; pediatric-onset OCD shows the highest heritability (45-65%)10,11. Genome-wide association studies (PGC-OCD) implicate genes involved in glutamatergic and serotonergic signaling15,34. Genetics confers vulnerability, but environment determines expression; identical twins do not always both develop OCD10.

Section 2 — Symptoms, Themes & “Pure O”

11. What is “Pure O” OCD?

“Pure O” (purely obsessional OCD) is a popular but somewhat misleading term for OCD where compulsions are predominantly mental rather than visible behaviours35,36. People with “Pure O” still perform compulsions — they just look like rumination, mental reviewing, mental neutralizing, silent prayer, reassurance-seeking, or mental checking. Modern OCD experts (Steven Phillipson, Jon Hershfield, Jon Grayson) emphasize that recognizing these mental compulsions is essential for effective treatment36,37.

12. What is Harm OCD? (intrusive thoughts about hurting others)

Harm OCD involves unwanted, intrusive thoughts, images, or urges about harming oneself or others — the person finds these thoughts horrifying and is the opposite of dangerous37,38. Compulsions include avoidance of knives or sharp objects, mental checking, reassurance-seeking, and confessing. Research is unequivocal: people with Harm OCD are not at increased risk of acting on these thoughts — these are ego-dystonic obsessions, not violent ideation38,39.

13. What is Sexual-Orientation OCD (HOCD/SO-OCD)?

SO-OCD involves obsessive doubt about one’s sexual orientation — for example, a heterosexual person tormented by intrusive thoughts that they might be gay, or vice versa37,40. The hallmark is distress and doubt about a settled identity, not genuine identity exploration. Compulsions include mental checking of arousal, “groinal response” monitoring, comparing to past attractions, and reassurance-seeking40,41. Treatment is the same as other OCD subtypes: ERP targeting the doubt itself, not the orientation question.

14. What is Pedophilia OCD (POCD)?

POCD involves intrusive, unwanted thoughts of being sexually attracted to children — extremely distressing to the sufferer, who has no genuine attraction37,41. Critically, POCD is the opposite of pedophilia: the obsessive person is repulsed and terrified by the thoughts; an actual offender is not39,41. Avoidance of children, mental checking of arousal, and reassurance-seeking are common compulsions. POCD responds well to ERP with a clinician trained in taboo-themed OCD37,42.

15. What is Relationship OCD (ROCD)?

ROCD involves obsessive doubts about whether one truly loves their partner, whether the partner is “the one,” or focused on the partner’s perceived flaws (Doron, Derby & Szepsenwol)43,44. Compulsions include mental comparing, checking feelings, reading relationship blogs, reassurance-seeking, and testing attraction. ROCD is associated with poorer relationship satisfaction but responds to standard OCD treatments adapted for relationship content44,45.

16. What is Religious/Scrupulosity OCD?

Scrupulosity OCD involves obsessive fear of having sinned, blasphemed, or violated moral/religious rules46,47. Compulsions include excessive prayer, confession, mental review of past actions, reassurance-seeking from clergy, and avoidance of religious activity. Effective treatment requires distinguishing between healthy faith practice and OCD-driven ritual; collaboration with culturally informed clergy can support recovery47,48.

17. What is Contamination OCD?

Contamination OCD is the most recognizable subtype, involving fear of germs, dirt, illness, chemicals, or “mental contamination” (a sense of internal dirtiness, often after trauma or moral violation)49,50. Compulsions include excessive washing, sanitizing, avoidance of “contaminated” places, and changing clothes50. Standard ERP — exposure to feared contaminants without washing — has very strong evidence; refractory cases benefit from inhibitory-learning approaches51,52.

18. What is “Just Right” OCD / symmetry OCD?

This subtype is driven by a feeling that something is “off” or incomplete rather than by anxiety about a feared outcome — what Rachman called incompleteness27,53. Compulsions include arranging, ordering, repeating actions until they “feel right,” and tapping. Just-right OCD overlaps with tic disorders and Tourette syndrome and may respond particularly well to ERP combined with habit-reversal training53,54.

19. What is Health/Somatic OCD?

Health-focused OCD (sometimes called Somatic OCD or overlapping with Illness Anxiety Disorder) involves obsessive worry about having or developing serious illness — cancer, ALS, MS, HIV — accompanied by body checking, online symptom searching (“cyberchondria”), and reassurance-seeking from doctors55,56. ERP combined with limits on reassurance-seeking and medical googling is the evidence-based treatment56,57.

20. What are mental compulsions and rumination?

Mental compulsions are internal rituals: silent prayer, counting, mental reviewing, “neutralizing” a bad thought with a good one, reassurance-seeking from one’s own memory, mental argument, or reasoning oneself out of doubt36,37. They function exactly like overt compulsions but are harder to recognize. Rumination — repetitive analysis of intrusive thoughts — is a particularly common and treatment-resistant mental compulsion58,59. Treatment requires labeling rumination as a compulsion and applying response prevention.

Section 3 — Diagnosis & What OCD Is NOT

21. How is OCD diagnosed?

OCD is diagnosed clinically using DSM-5-TR or ICD-11 criteria, supplemented by validated rating scales1,3. The Yale-Brown Obsessive Compulsive Scale (Y-BOCS) — and its updated Y-BOCS-II — is the gold-standard instrument for measuring severity (subclinical 0-7, mild 8-15, moderate 16-23, severe 24-31, extreme 32-40)60,61. The Dimensional Obsessive-Compulsive Scale (DOCS) and Obsessive-Compulsive Inventory-Revised (OCI-R) are also widely used62,63.

22. What’s the difference between intrusive thoughts and OCD?

Everyone has intrusive thoughts. Rachman & de Silva (1978) and Radomsky et al.’s 2014 international study (777 participants in 13 countries, 6 continents) found that ~94% of non-clinical people experience intrusive thoughts identical in content to those reported by OCD sufferers64,65. The difference isn’t the thought — it’s the response. Non-OCD people dismiss the thought; OCD sufferers attach meaning (“this means I’m dangerous”) and engage compulsions, which reinforces the cycle4,65.

23. Does everyone have intrusive thoughts?

Yes — see Q22. The seminal Rachman-de Silva study and Radomsky’s cross-cultural replication confirm intrusive thoughts about violence, sex, blasphemy, doubt, and contamination are universal human experiences64,65. What turns an intrusive thought into an obsession is misinterpretation of the thought as meaningful, dangerous, or revealing of one’s character (Salkovskis’s cognitive model)4,66.

24. Is OCD the same as being neat or organized?

No. Casual use of “I’m so OCD” trivializes a serious mental illness67,68. OCD involves significant distress and impairment — people with OCD often cannot stop their rituals, lose hours daily to them, and experience profound suffering. Liking organization or cleanliness without distress, time consumption, or impairment is not OCD1,68.

25. Can OCD be misdiagnosed as anxiety, depression, or psychosis?

Yes — OCD is widely misdiagnosed and is, on average, diagnosed 11-17 years after symptom onset69,70. Common misdiagnoses include generalized anxiety disorder, depression, schizophrenia (when bizarre obsessions are mistaken for delusions), or autism (when rituals are mistaken for stims)70,71. The OCD specifier “with poor or absent insight” applies when the person is highly convinced their fears are realistic; this is still OCD, not psychosis1,72.

26. What conditions commonly co-occur with OCD?

OCD has high comorbidity. The largest epidemiological studies show: major depression (~40-60%), anxiety disorders (~75% lifetime), tic disorders/Tourette (~10-30%), eating disorders, ADHD, autism, body dysmorphic disorder, and substance use23,73,74. Treating OCD often improves comorbid depression; severe depression may need to be addressed first to enable engagement in ERP74,75.

27. Is OCD a form of autism or ADHD?

No — they are separate conditions, but they overlap and frequently co-occur76,77. Both autism and OCD can involve repetitive behaviours, but autistic repetitive behaviours (stims, special interests) are typically pleasurable or regulating, while OCD compulsions are distressing and performed to neutralize obsessions76,78. Around 17-37% of autistic individuals also meet OCD criteria; OCD treatment may need autism-informed adaptations77,78.

28. Can OCD cause depression or suicidal thoughts?

Yes. OCD is associated with elevated rates of major depression (40-60% lifetime) and increased suicide risk — meta-analyses estimate ~26% lifetime suicidal ideation, ~13% lifetime attempts, with risk roughly 10-fold higher than in the general population79,80. Risk factors include severity, depression, taboo themes (harm/sexual), and untreated illness80. Treatment substantially reduces both depression and suicide risk80,81.

29. How long does it take to be diagnosed with OCD?

The IOCDF and multiple epidemiological studies report a typical delay of 11-17 years between symptom onset and accurate diagnosis69,70. Reasons include shame about taboo content, lack of clinician training, misdiagnosis, and the secretive nature of mental compulsions. Reducing this delay is a major IOCDF advocacy priority70,82.

30. Is OCD a disability?

Severe OCD can be disabling. The WHO ranks OCD among the top causes of YLD (years lived with disability), and the Americans with Disabilities Act (ADA) and Canadian human rights legislation recognize it as a qualifying mental disability when it substantially limits major life activities25,83. With evidence-based treatment, most people achieve substantial improvement and reduced functional impairment84,85.

Section 4 — Treatment: ERP, CBT, Medication & New Options

31. What is ERP (Exposure and Response Prevention)?

ERP, developed by Victor Meyer and refined by Edna Foa, Stanley Rachman, and Jonathan Abramowitz, is the gold-standard psychotherapy for OCD86,87. The patient is gradually exposed to feared situations or thoughts (in vivo, imaginal, or interoceptive exposures) while voluntarily refraining from compulsions (“response prevention”)88,89. Over repeated exposures, the brain learns the feared outcome doesn’t happen and that anxiety naturally subsides — a process called inhibitory learning90,91.

32. Why is ERP considered the gold-standard?

Decades of RCTs and Cochrane reviews show ERP produces large effect sizes (Cohen’s d ≈ 1.0-1.5), with ~70% of treatment completers showing clinically significant improvement88,92,93. ERP is recommended as first-line treatment by APA, NICE (CG31), AACAP, and the Canadian Network for Mood and Anxiety Treatments (CANMAT)94,95,96. ERP outperforms relaxation, anxiety management, and supportive therapy in head-to-head trials93,97.

33. How long does ERP therapy take to work?

Standard ERP protocols range from 13-20 weekly sessions, often with daily homework88,94. Most patients show meaningful improvement within 8-12 weeks. Intensive outpatient or residential ERP (3-5 hours/day for several weeks) produces faster results and is recommended for severe or treatment-resistant cases98,99. Gains are durable: long-term follow-ups (5+ years) show maintained benefits in most responders100.

34. What is I-CBT (Inference-Based CBT) for OCD?

Inference-Based CBT, developed by Frederick Aardema and Kieron O’Connor, targets the obsessional doubt itself — the inference that “maybe this could happen” — by helping patients distinguish reality from imagined possibility101,102. RCTs show I-CBT is comparable to ERP in effectiveness and may be especially useful for patients who struggle with exposure or have overvalued ideation102,103. It is gaining recognition as an evidence-based alternative or complement to ERP103.

35. What medications treat OCD?

First-line medications are serotonin reuptake inhibitors (SRIs): clomipramine and the SSRIs fluoxetine, fluvoxamine, sertraline, paroxetine, escitalopram, and citalopram104,105. OCD typically requires higher doses and longer trials (10-12 weeks) than depression105,106. About 40-60% respond to a first SRI; clomipramine is slightly more effective but has more side effects107,108. Augmentation strategies include low-dose antipsychotics (risperidone, aripiprazole) for partial responders109,110.

36. How long do OCD medications take to work?

Unlike depression, OCD medications often require 10-12 weeks at therapeutic doses for full effect105,106. Doses are typically higher than for depression (e.g., fluoxetine 60-80 mg, sertraline 200 mg, fluvoxamine 200-300 mg)94,105. If one SRI fails after an adequate trial, switching to another SRI yields response in another ~30-50% of patients107,111. Combining medication with ERP often yields the best long-term outcomes112.

37. Does ACT (Acceptance & Commitment Therapy) help OCD?

ACT, developed by Steven Hayes, teaches acceptance of intrusive thoughts as mental events without trying to control them, while committing to values-driven action113,114. Several RCTs (Twohig et al., 2010, 2018) show ACT is comparable to ERP and may be especially helpful for patients who refuse exposure work114,115. ACT is increasingly integrated with ERP rather than as a replacement115,116.

38. What about TMS, DBS, or ketamine for treatment-resistant OCD?

For treatment-resistant OCD (failed multiple SRI trials and ERP), several biological options have evidence: Deep Transcranial Magnetic Stimulation (dTMS) targeting the medial prefrontal cortex/anterior cingulate is FDA-cleared (2018) for OCD117,118. Deep Brain Stimulation (DBS) of the ventral capsule/ventral striatum has FDA Humanitarian Device Exemption for severe refractory OCD, with ~60% response rates in case series119,120. Ketamine shows rapid but transient anti-OCD effects in early trials121. Psilocybin trials are underway122.

39. Is OCD curable or just manageable?

OCD is generally considered a chronic, lifelong condition that can be brought into full or partial remission rather than “cured”123,124. Long-term studies show that with adequate ERP and/or medication, ~50-70% of patients achieve significant remission, though many continue to manage residual symptoms100,124. Even with relapse, re-engaging treatment typically restores gains84,124.

40. What if ERP feels too scary or doesn’t work?

Inability to start ERP is common, not a sign of failure. Options: (1) start with lower-intensity exposures or imaginal exposures; (2) add medication first to reduce baseline anxiety; (3) try I-CBT, ACT, or mindfulness-based approaches; (4) consider intensive or residential treatment; (5) for severe refractory cases, dTMS or DBS117,101,116. The most common reason ERP “fails” is undetected mental compulsions or reassurance-seeking — careful case formulation often unlocks treatment36,89.

Section 5 — Living with OCD: Daily Life, Relationships & Family

41. How do I stop doing compulsions?

Stopping compulsions is the core of OCD treatment but is rarely simple “willpower.” Evidence-based strategies: (1) label the compulsion — including subtle mental ones; (2) delay the compulsion (delay 5 min, then 10, then longer); (3) change the response rather than the thought — let the obsession exist without engaging88,89. Working with an ERP-trained clinician dramatically improves success rates. Self-help books based on ERP (Foa & Wilson, Abramowitz, Hershfield) have evidence for milder cases37,125.

42. How do I deal with intrusive thoughts without responding?

The cognitive-behavioural model says fighting or analyzing intrusive thoughts strengthens them — a paradoxical effect demonstrated in Wegner’s “white bear” experiments126,127. Effective approaches: notice the thought, label it (“that’s an intrusive thought”), let it pass without engaging, and redirect to your values-driven activity113,128. ACT calls this cognitive defusion; ERP calls it response prevention114,116.

43. What is “reassurance-seeking” and why is it harmful?

Reassurance-seeking — repeatedly asking others, googling, or mentally reviewing for confirmation that one’s fear isn’t true — is one of the most common covert compulsions129,130. It provides short-term relief but reinforces the obsession by signaling that the thought matters. Best practice: identify reassurance-seeking, gradually reduce or eliminate it (with the support of family/clinician), and tolerate the resulting uncertainty130,131.

44. How do I support a partner or family member with OCD?

The best support combines compassion with not participating in compulsions or accommodation132,133. IOCDF and clinical guidelines recommend: learn about OCD, be patient, encourage treatment, decline reassurance-seeking gently, support exposure practice, and avoid criticism or blame132,134. Family-based ERP shows strong evidence, especially for pediatric OCD135,136.

45. What is “family accommodation” and why does it make OCD worse?

Family accommodation — when loved ones provide reassurance, participate in rituals, or modify routines to reduce the OCD sufferer’s anxiety — is associated with worse OCD severity, poorer treatment response, and lower quality of life for both patient and family137,138. The Family Accommodation Scale (FAS-PR) measures this; reducing accommodation through SPACE (Eli Lebowitz) or family-based CBT improves outcomes139,140.

46. How do I parent a child with OCD?

Pediatric OCD affects ~1-3% of children. Evidence-based treatment is family-based CBT with ERP, often combined with SSRIs for moderate-severe cases (POTS trial)141,142. Parents are coached to: externalize OCD (“bossing OCD back”), reduce family accommodation, support exposure homework, and reinforce brave behaviour143,144. The IOCDF, AACAP guidelines, and the POTS treatment manuals provide structured frameworks96,141.

47. Can OCD get worse during pregnancy/postpartum?

Yes — pregnancy and postpartum are documented periods of OCD onset or exacerbation145,146. Perinatal OCD often involves intrusive thoughts of harming the baby; meta-analyses show postpartum prevalence of ~2-9%, much higher than baseline145,147. These thoughts are deeply distressing but not predictive of harm. Treatment includes ERP and, when needed, SSRIs (sertraline is generally considered safest in pregnancy/lactation)147,148.

48. Does stress make OCD worse?

Yes. Stress is a well-documented trigger for OCD onset, exacerbation, and relapse149,150. Major life transitions, sleep deprivation, illness, and trauma frequently precede flare-ups. Stress-management strategies — sleep hygiene, exercise, mindfulness, social support — complement (but do not replace) ERP and medication150,151.

49. Will my OCD theme switch?

Yes — theme-shifting (or “OCD theme jumping”) is well-recognized clinically and often distressing because it feels like the OCD is “winning”8,9. The themes are surface-level; the underlying mechanism (intolerance of uncertainty, attachment to compulsions) is the same. Treatment focuses on the process of OCD — not chasing each new theme — by building tolerance for uncertainty and refraining from compulsions regardless of content152,153.

50. Can OCD relapse, and how do I prevent it?

Yes — relapse rates after stopping treatment range from 25-65%, and OCD typically follows a chronic waxing-waning course100,154. Best practices for prevention: maintain ERP “exposure tune-ups,” continue medication if it has been helpful (premature discontinuation strongly predicts relapse), watch for early warning signs, manage stress and sleep, and re-engage your therapist early if symptoms re-emerge154,155. With consistent care, most people achieve and maintain meaningful recovery.

📚 References

  1. American Psychiatric Association. (2022). Diagnostic and Statistical Manual of Mental Disorders (5th ed., text rev.; DSM-5-TR). APA Publishing. https://doi.org/10.1176/appi.books.9780890425787
  2. Stein, D. J., Costa, D. L. C., Lochner, C., et al. (2019). Obsessive-compulsive disorder. Nature Reviews Disease Primers, 5, 52. https://doi.org/10.1038/s41572-019-0102-3
  3. World Health Organization. (2022). International Classification of Diseases, 11th Revision (ICD-11). https://icd.who.int
  4. Salkovskis, P. M. (1985). Obsessional-compulsive problems: A cognitive-behavioural analysis. Behaviour Research and Therapy, 23(5), 571-583. https://doi.org/10.1016/0005-7967(85)90105-6
  5. Mowrer, O. H. (1960). Learning Theory and Behavior. Wiley.
  6. Foa, E. B., & Kozak, M. J. (1986). Emotional processing of fear: Exposure to corrective information. Psychological Bulletin, 99(1), 20-35. https://doi.org/10.1037/0033-2909.99.1.20
  7. Mataix-Cols, D., Rosario-Campos, M. C., & Leckman, J. F. (2005). A multidimensional model of obsessive-compulsive disorder. American Journal of Psychiatry, 162(2), 228-238. https://doi.org/10.1176/appi.ajp.162.2.228
  8. Bloch, M. H., Landeros-Weisenberger, A., Rosario, M. C., et al. (2008). Meta-analysis of the symptom structure of obsessive-compulsive disorder. American Journal of Psychiatry, 165(12), 1532-1542. https://doi.org/10.1176/appi.ajp.2008.08020320
  9. Mataix-Cols, D., Rauch, S. L., Manzo, P. A., et al. (1999). Use of factor-analyzed symptom dimensions to predict outcome with serotonin reuptake inhibitors and placebo in OCD. American Journal of Psychiatry, 156(9), 1409-1416.
  10. Pauls, D. L., Abramovitch, A., Rauch, S. L., & Geller, D. A. (2014). Obsessive-compulsive disorder: An integrative genetic and neurobiological perspective. Nature Reviews Neuroscience, 15(6), 410-424. https://doi.org/10.1038/nrn3746
  11. Hettema, J. M., Neale, M. C., & Kendler, K. S. (2001). A review and meta-analysis of the genetic epidemiology of anxiety disorders. American Journal of Psychiatry, 158(10), 1568-1578.
  12. Saxena, S., & Rauch, S. L. (2000). Functional neuroimaging and the neuroanatomy of OCD. Psychiatric Clinics of North America, 23(3), 563-586. https://doi.org/10.1016/S0193-953X(05)70181-7
  13. Milad, M. R., & Rauch, S. L. (2012). Obsessive-compulsive disorder: Beyond segregated cortico-striatal pathways. Trends in Cognitive Sciences, 16(1), 43-51. https://doi.org/10.1016/j.tics.2011.11.003
  14. Goodman, W. K., Price, L. H., Rasmussen, S. A., et al. (1990). Specificity of serotonin reuptake inhibitors in OCD: Comparison of fluvoxamine and desipramine. Archives of General Psychiatry, 47(6), 577-585.
  15. Pittenger, C., Bloch, M. H., & Williams, K. (2011). Glutamate abnormalities in obsessive compulsive disorder: Neurobiology, pathophysiology, and treatment. Pharmacology & Therapeutics, 132(3), 314-332. https://doi.org/10.1016/j.pharmthera.2011.09.006
  16. Real, E., Labad, J., Alonso, P., et al. (2011). Stressful life events at onset of obsessive-compulsive disorder are associated with a distinct clinical pattern. Depression and Anxiety, 28(5), 367-376. https://doi.org/10.1002/da.20792
  17. Rachman, S. (1997). A cognitive theory of obsessions. Behaviour Research and Therapy, 35(9), 793-802. https://doi.org/10.1016/S0005-7967(97)00040-5
  18. Schwartz, J. M., Stoessel, P. W., Baxter, L. R., Martin, K. M., & Phelps, M. E. (1996). Systematic changes in cerebral glucose metabolic rate after successful behavior modification treatment of OCD. Archives of General Psychiatry, 53(2), 109-113. https://doi.org/10.1001/archpsyc.1996.01830020023004
  19. Foa, E. B., Liebowitz, M. R., Kozak, M. J., et al. (2005). Randomized, placebo-controlled trial of exposure and ritual prevention, clomipramine, and their combination in the treatment of OCD. American Journal of Psychiatry, 162(1), 151-161.
  20. Simpson, H. B., Foa, E. B., Liebowitz, M. R., et al. (2008). A randomized, controlled trial of cognitive-behavioral therapy for augmenting pharmacotherapy in OCD. American Journal of Psychiatry, 165(5), 621-630. https://doi.org/10.1176/appi.ajp.2007.07091440
  21. Ruscio, A. M., Stein, D. J., Chiu, W. T., & Kessler, R. C. (2010). The epidemiology of obsessive-compulsive disorder in the National Comorbidity Survey Replication. Molecular Psychiatry, 15(1), 53-63. https://doi.org/10.1038/mp.2008.94
  22. Kessler, R. C., Petukhova, M., Sampson, N. A., et al. (2012). Twelve-month and lifetime prevalence and lifetime morbid risk of anxiety and mood disorders in the United States. International Journal of Methods in Psychiatric Research, 21(3), 169-184.
  23. Geller, D. A. (2006). Obsessive-compulsive and spectrum disorders in children and adolescents. Psychiatric Clinics of North America, 29(2), 353-370.
  24. Skoog, G., & Skoog, I. (1999). A 40-year follow-up of patients with obsessive-compulsive disorder. Archives of General Psychiatry, 56(2), 121-127.
  25. World Health Organization. (2008). The Global Burden of Disease: 2004 Update. WHO.
  26. Olatunji, B. O., Cisler, J. M., & Tolin, D. F. (2010). A meta-analysis of the influence of comorbidity on treatment outcome in the anxiety disorders. Clinical Psychology Review, 30(6), 642-654.
  27. Coles, M. E., Frost, R. O., Heimberg, R. G., & Rhéaume, J. (2003). “Not just right experiences”: Perfectionism, obsessive-compulsive features and general psychopathology. Behaviour Research and Therapy, 41(6), 681-700.
  28. Pinto, A., Eisen, J. L., Mancebo, M. C., & Rasmussen, S. A. (2008). Obsessive-compulsive personality disorder. In J. S. Abramowitz, D. McKay, & S. Taylor (Eds.), Obsessive-Compulsive Disorder: Subtypes and Spectrum Conditions (pp. 246-263). Elsevier.
  29. Diedrich, A., & Voderholzer, U. (2015). Obsessive-compulsive personality disorder: A current review. Current Psychiatry Reports, 17(2), 2. https://doi.org/10.1007/s11920-014-0547-8
  30. Swedo, S. E., Leonard, H. L., Garvey, M., et al. (1998). Pediatric autoimmune neuropsychiatric disorders associated with streptococcal infections: Clinical description of the first 50 cases. American Journal of Psychiatry, 155(2), 264-271.
  31. Chang, K., Frankovich, J., Cooperstock, M., et al. (2015). Clinical evaluation of youth with pediatric acute-onset neuropsychiatric syndrome (PANS): Recommendations from the 2013 PANS Consensus Conference. Journal of Child and Adolescent Psychopharmacology, 25(1), 3-13.
  32. Berthier, M. L., Kulisevsky, J., Gironell, A., & Heras, J. A. (1996). Obsessive-compulsive disorder associated with brain lesions: Clinical phenomenology, cognitive function, and anatomic correlates. Neurology, 47(2), 353-361.
  33. Banerjee, D., Vajawat, B., Varshney, P., & Rao, T. S. S. (2021). Pandemic, OCD, and disinfection: Evolving relationship in the times of COVID-19. Asian Journal of Psychiatry, 56, 102553. https://doi.org/10.1016/j.ajp.2021.102553
  34. International Obsessive Compulsive Disorder Foundation Genetics Collaborative (IOCDF-GC). (2018). Revealing the complex genetic architecture of obsessive-compulsive disorder using meta-analysis. Molecular Psychiatry, 23(5), 1181-1188. https://doi.org/10.1038/mp.2017.154
  35. Williams, M. T., Farris, S. G., Turkheimer, E., et al. (2011). Myth of the pure obsessional type in obsessive-compulsive disorder. Depression and Anxiety, 28(6), 495-500. https://doi.org/10.1002/da.20820
  36. Phillipson, S. (2014). OCD: Obsessions and Compulsions: Pure-O. Center for Cognitive-Behavioral Psychotherapy.
  37. Hershfield, J., & Corboy, T. (2020). The Mindfulness Workbook for OCD (2nd ed.). New Harbinger.
  38. Moulding, R., Aardema, F., & O’Connor, K. P. (2014). Repugnant obsessions: A review of the phenomenology, theoretical models, and treatment of sexual and aggressive obsessional themes in OCD. Journal of Obsessive-Compulsive and Related Disorders, 3(2), 161-168.
  39. Veale, D., Freeston, M., Krebs, G., Heyman, I., & Salkovskis, P. (2009). Risk assessment and management in obsessive-compulsive disorder. Advances in Psychiatric Treatment, 15(5), 332-343.
  40. Williams, M. T., & Farris, S. G. (2011). Sexual orientation obsessions in obsessive-compulsive disorder: Prevalence and correlates. Psychiatry Research, 187(1-2), 156-159. https://doi.org/10.1016/j.psychres.2010.10.019
  1. Glazier, K., Wetterneck, C., Singh, S., & Williams, M. T. (2015). Stigma and shame as barriers to treatment for obsessive-compulsive and related disorders. Journal of Depression and Anxiety, 4(3), 191. https://doi.org/10.4172/2167-1044.1000191
  2. Williams, M. T., Mugno, B., Franklin, M., & Faber, S. (2013). Symptom dimensions in obsessive-compulsive disorder: Phenomenology and treatment outcomes with exposure and ritual prevention. Psychopathology, 46(6), 365-376.
  3. Doron, G., Derby, D. S., Szepsenwol, O., & Talmor, D. (2012). Tainted love: Exploring relationship-centered obsessive compulsive symptoms in two non-clinical cohorts. Journal of Obsessive-Compulsive and Related Disorders, 1(1), 16-24. https://doi.org/10.1016/j.jocrd.2011.11.002
  4. Doron, G., Derby, D. S., & Szepsenwol, O. (2014). Relationship obsessive compulsive disorder (ROCD): A conceptual framework. Journal of Obsessive-Compulsive and Related Disorders, 3(2), 169-180.
  5. Melli, G., Bulli, F., Doron, G., & Carraresi, C. (2018). Maladaptive beliefs in relationship obsessive compulsive disorder (ROCD): Replication and extension in a clinical sample. Journal of Obsessive-Compulsive and Related Disorders, 18, 47-53.
  6. Abramowitz, J. S., Huppert, J. D., Cohen, A. B., Tolin, D. F., & Cahill, S. P. (2002). Religious obsessions and compulsions in a non-clinical sample: The Penn Inventory of Scrupulosity (PIOS). Behaviour Research and Therapy, 40(7), 825-838.
  7. Huppert, J. D., Siev, J., & Kushner, E. S. (2007). When religion and obsessive-compulsive disorder collide: Treating scrupulosity in ultra-orthodox Jews. Journal of Clinical Psychology, 63(10), 925-941.
  8. Siev, J., Steketee, G., Fama, J. M., & Wilhelm, S. (2011). Cognitive and clinical characteristics of sexual and religious obsessions. Journal of Cognitive Psychotherapy, 25(3), 167-176.
  9. Rachman, S. (2004). Fear of contamination. Behaviour Research and Therapy, 42(11), 1227-1255. https://doi.org/10.1016/j.brat.2003.10.009
  10. Rachman, S. (2006). The Fear of Contamination: Assessment and Treatment. Oxford University Press.
  11. Foa, E. B., Yadin, E., & Lichner, T. K. (2012). Exposure and Response (Ritual) Prevention for Obsessive-Compulsive Disorder: Therapist Guide (2nd ed.). Oxford University Press.
  12. Craske, M. G., Treanor, M., Conway, C. C., Zbozinek, T., & Vervliet, B. (2014). Maximizing exposure therapy: An inhibitory learning approach. Behaviour Research and Therapy, 58, 10-23. https://doi.org/10.1016/j.brat.2014.04.006
  13. Summerfeldt, L. J. (2004). Understanding and treating incompleteness in obsessive-compulsive disorder. Journal of Clinical Psychology, 60(11), 1155-1168. https://doi.org/10.1002/jclp.20080
  14. Leckman, J. F., Walker, D. E., & Cohen, D. J. (1993). Premonitory urges in Tourette’s syndrome. American Journal of Psychiatry, 150(1), 98-102.
  15. Asmundson, G. J. G., Taylor, S., & Cox, B. J. (2001). Health Anxiety: Clinical and Research Perspectives on Hypochondriasis and Related Conditions. Wiley.
  16. Cooper, K., Gregory, J. D., Walker, I., Lambe, S., & Salkovskis, P. M. (2017). Cognitive behaviour therapy for health anxiety: A systematic review and meta-analysis. Behavioural and Cognitive Psychotherapy, 45(2), 110-123. https://doi.org/10.1017/S1352465816000527
  17. Newby, J. M., McKinnon, A., Kuyken, W., Gilbody, S., & Dalgleish, T. (2015). Systematic review and meta-analysis of transdiagnostic psychological treatments for anxiety and depressive disorders in adulthood. Clinical Psychology Review, 40, 91-110.
  18. Wahl, K., Ehring, T., Kley, H., et al. (2019). Is repetitive negative thinking a transdiagnostic process? A systematic review of investigations of the repetitive thinking questionnaire as a measure of depressive rumination, worry, and post-event processing. Journal of Affective Disorders, 224, 135-152.
  19. Watkins, E. R. (2008). Constructive and unconstructive repetitive thought. Psychological Bulletin, 134(2), 163-206. https://doi.org/10.1037/0033-2909.134.2.163
  20. Goodman, W. K., Price, L. H., Rasmussen, S. A., et al. (1989). The Yale-Brown Obsessive Compulsive Scale: I. Development, use, and reliability. Archives of General Psychiatry, 46(11), 1006-1011. https://doi.org/10.1001/archpsyc.1989.01810110048007
  21. Storch, E. A., Rasmussen, S. A., Price, L. H., et al. (2010). Development and psychometric evaluation of the Yale-Brown Obsessive-Compulsive Scale—Second Edition. Psychological Assessment, 22(2), 223-232. https://doi.org/10.1037/a0018492
  22. Abramowitz, J. S., Deacon, B. J., Olatunji, B. O., et al. (2010). Assessment of obsessive-compulsive symptom dimensions: Development and evaluation of the Dimensional Obsessive-Compulsive Scale. Psychological Assessment, 22(1), 180-198.
  23. Foa, E. B., Huppert, J. D., Leiberg, S., et al. (2002). The Obsessive-Compulsive Inventory: Development and validation of a short version. Psychological Assessment, 14(4), 485-496.
  24. Rachman, S., & de Silva, P. (1978). Abnormal and normal obsessions. Behaviour Research and Therapy, 16(4), 233-248. https://doi.org/10.1016/0005-7967(78)90022-0
  25. Radomsky, A. S., Alcolado, G. M., Abramowitz, J. S., et al. (2014). Part 1—You can run but you can’t hide: Intrusive thoughts on six continents. Journal of Obsessive-Compulsive and Related Disorders, 3(3), 269-279. https://doi.org/10.1016/j.jocrd.2013.09.002
  26. Salkovskis, P. M., Forrester, E., & Richards, C. (1998). Cognitive-behavioural approach to understanding obsessional thinking. British Journal of Psychiatry, 173(35), 53-63.
  27. Pavelko, R. L., & Myrick, J. G. (2015). That’s so OCD: The effects of disease trivialization via social media on user perceptions and impression formation. Computers in Human Behavior, 49, 251-258. https://doi.org/10.1016/j.chb.2015.02.061
  28. McKay, D., Abramowitz, J. S., & Storch, E. A. (2017). Mechanisms of harmful treatments for obsessive-compulsive disorder. Clinical Psychology: Science and Practice, 24(1), 76-79.
  29. Jenike, M. A. (2004). Obsessive-compulsive disorder. New England Journal of Medicine, 350(3), 259-265. https://doi.org/10.1056/NEJMcp031002
  30. Glazier, K., Calixte, R. M., Rothschild, R., & Pinto, A. (2013). High rates of OCD symptom misidentification by mental health professionals. Annals of Clinical Psychiatry, 25(3), 201-209.
  31. Catapano, F., Perris, F., Masella, M., et al. (2010). Obsessive-compulsive disorder: A 3-year prospective follow-up study of patients treated with serotonin reuptake inhibitors. Journal of Psychiatric Research, 44(2), 91-95.
  32. Foa, E. B., Abramowitz, J. S., Franklin, M. E., & Kozak, M. J. (1999). Feared consequences, fixity of belief, and treatment outcome in patients with obsessive-compulsive disorder. Behavior Therapy, 30(4), 717-724.
  33. LaSalle, V. H., Cromer, K. R., Nelson, K. N., et al. (2004). Diagnostic interview assessed neuropsychiatric disorder comorbidity in 334 individuals with obsessive-compulsive disorder. Depression and Anxiety, 19(3), 163-173.
  34. Pallanti, S., Grassi, G., Sarrecchia, E. D., Cantisani, A., & Pellegrini, M. (2011). Obsessive-compulsive disorder comorbidity: Clinical assessment and therapeutic implications. Frontiers in Psychiatry, 2, 70. https://doi.org/10.3389/fpsyt.2011.00070
  35. Abramowitz, J. S. (2004). Treatment of obsessive-compulsive disorder in patients who have comorbid major depression. Journal of Clinical Psychology, 60(11), 1133-1141.
  36. Mack, H., Fullana, M. A., Russell, A. J., Mataix-Cols, D., Nakatani, E., & Heyman, I. (2010). Obsessions and compulsions in children with Asperger’s syndrome or high-functioning autism: A case-control study. Australian and New Zealand Journal of Psychiatry, 44(12), 1082-1088.
  37. van Steensel, F. J. A., Bögels, S. M., & Perrin, S. (2011). Anxiety disorders in children and adolescents with autistic spectrum disorders: A meta-analysis. Clinical Child and Family Psychology Review, 14(3), 302-317.
  38. Russell, A. J., Jassi, A., Fullana, M. A., et al. (2013). Cognitive behavior therapy for comorbid obsessive-compulsive disorder in high-functioning autism spectrum disorders: A randomized controlled trial. Depression and Anxiety, 30(8), 697-708.
  39. Angelakis, I., Gooding, P., Tarrier, N., & Panagioti, M. (2015). Suicidality in obsessive compulsive disorder (OCD): A systematic review and meta-analysis. Clinical Psychology Review, 39, 1-15. https://doi.org/10.1016/j.cpr.2015.03.002
  40. Albert, U., De Ronchi, D., Maina, G., & Pompili, M. (2019). Suicide risk in obsessive-compulsive disorder and exploration of risk factors: A systematic review. Current Neuropharmacology, 17(8), 681-696.
  1. Eisen, J. L., Sibrava, N. J., Boisseau, C. L., et al. (2013). Five-year course of obsessive-compulsive disorder: Predictors of remission and relapse. Journal of Clinical Psychiatry, 74(3), 233-239.
  2. International OCD Foundation. (2024). About OCD. https://iocdf.org/about-ocd/
  3. Subramaniam, M., Soh, P., Vaingankar, J. A., Picco, L., & Chong, S. A. (2013). Quality of life in obsessive-compulsive disorder: Impact of the disorder and of treatment. CNS Drugs, 27(5), 367-383.
  4. Eisen, J. L., Pinto, A., Mancebo, M. C., Dyck, I. R., Orlando, M. E., & Rasmussen, S. A. (2010). A 2-year prospective follow-up study of the course of obsessive-compulsive disorder. Journal of Clinical Psychiatry, 71(8), 1033-1039.
  5. Macy, A. S., Theo, J. N., Kaufmann, S. C. V., et al. (2013). Quality of life in obsessive compulsive disorder. CNS Spectrums, 18(1), 21-33.
  6. Meyer, V. (1966). Modification of expectations in cases with obsessional rituals. Behaviour Research and Therapy, 4(4), 273-280. https://doi.org/10.1016/0005-7967(66)90083-0
  7. Foa, E. B., Steketee, G., & Milby, J. B. (1980). Differential effects of exposure and response prevention in obsessive-compulsive washers. Journal of Consulting and Clinical Psychology, 48(1), 71-79.
  8. Abramowitz, J. S. (2006). The psychological treatment of obsessive-compulsive disorder. Canadian Journal of Psychiatry, 51(7), 407-416. https://doi.org/10.1177/070674370605100702
  9. Foa, E. B. (2010). Cognitive behavioral therapy of obsessive-compulsive disorder. Dialogues in Clinical Neuroscience, 12(2), 199-207.
  10. Craske, M. G., Kircanski, K., Zelikowsky, M., Mystkowski, J., Chowdhury, N., & Baker, A. (2008). Optimizing inhibitory learning during exposure therapy. Behaviour Research and Therapy, 46(1), 5-27. https://doi.org/10.1016/j.brat.2007.10.003
  11. Jacoby, R. J., & Abramowitz, J. S. (2016). Inhibitory learning approaches to exposure therapy: A critical review and translation to obsessive-compulsive disorder. Clinical Psychology Review, 49, 28-40.
  12. Olatunji, B. O., Davis, M. L., Powers, M. B., & Smits, J. A. (2013). Cognitive-behavioral therapy for obsessive-compulsive disorder: A meta-analysis of treatment outcome and moderators. Journal of Psychiatric Research, 47(1), 33-41. https://doi.org/10.1016/j.jpsychires.2012.08.020
  13. Skapinakis, P., Caldwell, D. M., Hollingworth, W., et al. (2016). Pharmacological and psychotherapeutic interventions for management of obsessive-compulsive disorder in adults: A systematic review and network meta-analysis. The Lancet Psychiatry, 3(8), 730-739.
  14. Koran, L. M., Hanna, G. L., Hollander, E., Nestadt, G., & Simpson, H. B. (2007). Practice guideline for the treatment of patients with obsessive-compulsive disorder. American Journal of Psychiatry, 164(7 Suppl), 5-53.
  15. National Institute for Health and Care Excellence (NICE). (2005, updated). Obsessive-compulsive disorder and body dysmorphic disorder: Treatment [CG31]. https://www.nice.org.uk/guidance/cg31
  16. Geller, D. A., & March, J. (2012). Practice parameter for the assessment and treatment of children and adolescents with obsessive-compulsive disorder. Journal of the American Academy of Child & Adolescent Psychiatry, 51(1), 98-113.
  17. Simpson, H. B., Foa, E. B., Liebowitz, M. R., et al. (2013). Cognitive-behavioral therapy vs risperidone for augmenting serotonin reuptake inhibitors in obsessive-compulsive disorder. JAMA Psychiatry, 70(11), 1190-1199.
  18. Stewart, S. E., Stack, D. E., Farrell, C., Pauls, D. L., & Jenike, M. A. (2005). Effectiveness of intensive residential treatment (IRT) for severe, refractory obsessive-compulsive disorder. Journal of Psychiatric Research, 39(6), 603-609.
  19. Veale, D., Naismith, I., Miles, S., Gledhill, L. J., Stewart, G., & Hodsoll, J. (2016). Outcomes for residential or inpatient intensive treatment of obsessive-compulsive disorder: A systematic review and meta-analysis. Journal of Obsessive-Compulsive and Related Disorders, 8, 38-49.
  20. Foa, E. B., Liebowitz, M. R., Kozak, M. J., et al. (2005). Long-term effectiveness of exposure and ritual prevention for OCD. Journal of Clinical Psychiatry, 66(10), 1295-1304.
  21. O’Connor, K. P., Aardema, F., & Pélissier, M.-C. (2005). Beyond Reasonable Doubt: Reasoning Processes in Obsessive-Compulsive Disorder and Related Disorders. Wiley.
  22. Aardema, F., Wong, S. F., Audet, J. S., et al. (2022). Reduced obsessive beliefs after inference-based therapy: A randomized clinical trial. Frontiers in Psychiatry, 13, 911249. https://doi.org/10.3389/fpsyt.2022.911249
  23. Visser, H. A., van Megen, H., van Oppen, P., et al. (2015). Inference-based approach versus cognitive behavioral therapy in the treatment of obsessive-compulsive disorder with poor insight: A 24-session randomized controlled trial. Psychotherapy and Psychosomatics, 84(5), 284-293.
  24. Soomro, G. M., Altman, D. G., Rajagopal, S., & Oakley-Browne, M. (2008). Selective serotonin re-uptake inhibitors (SSRIs) versus placebo for obsessive compulsive disorder (OCD). Cochrane Database of Systematic Reviews, (1), CD001765. https://doi.org/10.1002/14651858.CD001765.pub3
  25. Bloch, M. H., McGuire, J., Landeros-Weisenberger, A., Leckman, J. F., & Pittenger, C. (2010). Meta-analysis of the dose-response relationship of SSRI in obsessive-compulsive disorder. Molecular Psychiatry, 15(8), 850-855. https://doi.org/10.1038/mp.2009.50
  26. Pittenger, C., & Bloch, M. H. (2014). Pharmacological treatment of obsessive-compulsive disorder. Psychiatric Clinics of North America, 37(3), 375-391.
  27. Greist, J. H., Jefferson, J. W., Kobak, K. A., Katzelnick, D. J., & Serlin, R. C. (1995). Efficacy and tolerability of serotonin transport inhibitors in obsessive-compulsive disorder: A meta-analysis. Archives of General Psychiatry, 52(1), 53-60.
  28. Clomipramine Collaborative Study Group. (1991). Clomipramine in the treatment of patients with obsessive-compulsive disorder. Archives of General Psychiatry, 48(8), 730-738.
  29. Veale, D., Miles, S., Smallcombe, N., Ghezai, H., Goldacre, B., & Hodsoll, J. (2014). Atypical antipsychotic augmentation in SSRI treatment refractory obsessive-compulsive disorder: A systematic review and meta-analysis. BMC Psychiatry, 14, 317.
  30. Dold, M., Aigner, M., Lanzenberger, R., & Kasper, S. (2015). Antipsychotic augmentation of serotonin reuptake inhibitors in treatment-resistant obsessive-compulsive disorder: An update meta-analysis of double-blind, randomized, placebo-controlled trials. International Journal of Neuropsychopharmacology, 18(9), pyv047.
  31. Pallanti, S., Hollander, E., Bienstock, C., et al. (2002). Treatment non-response in OCD: Methodological issues and operational definitions. International Journal of Neuropsychopharmacology, 5(2), 181-191.
  32. Romanelli, R. J., Wu, F. M., Gamba, R., Mojtabai, R., & Segal, J. B. (2014). Behavioral therapy and serotonin reuptake inhibitor pharmacotherapy in the treatment of obsessive-compulsive disorder: A systematic review and meta-analysis of head-to-head randomized controlled trials. Depression and Anxiety, 31(8), 641-652.
  33. Hayes, S. C., Strosahl, K. D., & Wilson, K. G. (2011). Acceptance and Commitment Therapy: The Process and Practice of Mindful Change (2nd ed.). Guilford.
  34. Twohig, M. P., Hayes, S. C., Plumb, J. C., et al. (2010). A randomized clinical trial of acceptance and commitment therapy versus progressive relaxation training for obsessive-compulsive disorder. Journal of Consulting and Clinical Psychology, 78(5), 705-716. https://doi.org/10.1037/a0020508
  35. Twohig, M. P., Abramowitz, J. S., Smith, B. M., et al. (2018). Adding acceptance and commitment therapy to exposure and response prevention for obsessive-compulsive disorder: A randomized controlled trial. Behaviour Research and Therapy, 108, 1-9.
  36. Bluett, E. J., Homan, K. J., Morrison, K. L., Levin, M. E., & Twohig, M. P. (2014). Acceptance and commitment therapy for anxiety and OCD spectrum disorders: An empirical review. Journal of Anxiety Disorders, 28(6), 612-624.
  37. Carmi, L., Tendler, A., Bystritsky, A., et al. (2019). Efficacy and safety of deep transcranial magnetic stimulation for obsessive-compulsive disorder: A prospective multicenter randomized double-blind placebo-controlled trial. American Journal of Psychiatry, 176(11), 931-938. https://doi.org/10.1176/appi.ajp.2019.18101180
  38. Trevizol, A. P., Shiozawa, P., Cook, I. A., et al. (2016). Transcranial magnetic stimulation for obsessive-compulsive disorder: An updated systematic review and meta-analysis. Journal of ECT, 32(4), 262-266.
  39. Greenberg, B. D., Gabriels, L. A., Malone, D. A., et al. (2010). Deep brain stimulation of the ventral internal capsule/ventral striatum for obsessive-compulsive disorder: Worldwide experience. Molecular Psychiatry, 15(1), 64-79. https://doi.org/10.1038/mp.2008.55
  40. Kisely, S., Hall, K., Siskind, D., Frater, J., Olson, S., & Crompton, D. (2014). Deep brain stimulation for obsessive-compulsive disorder: A systematic review and meta-analysis. Psychological Medicine, 44(16), 3533-3542.

References (121–155)

  1. Mancebo MC, et al. Long-term course of OCD: 10-year follow-up of the Brown Longitudinal Study. J Clin Psychiatry. 2020;81(6):20m13267.
  2. Eisen JL, et al. Five-year course of OCD: predictors of remission and relapse. J Clin Psychiatry. 2013;74(3):233-239.
  3. Simpson HB, et al. Patterns of remission and recurrence in OCD: a 2-year follow-up. J Clin Psychiatry. 2006;67(2):269-276.
  4. Foa EB, et al. Six-month follow-up of randomized trial of exposure and ritual prevention plus medication. Am J Psychiatry. 2013;170(11):1294-1303.
  5. Whittal ML, et al. Group and individual treatment of OCD using cognitive therapy and exposure plus response prevention: 2-year follow-up. J Consult Clin Psychol. 2008;76(6):1003-1014.
  6. IOCDF. Family Guidelines for Living with OCD. International OCD Foundation; 2023.
  7. Lebowitz ER, et al. SPACE: Supportive Parenting for Anxious Childhood Emotions—a parent-based treatment. J Am Acad Child Adolesc Psychiatry. 2020;59(3):362-372.
  8. Thompson-Hollands J, et al. Family accommodation in pediatric OCD: associations with symptom severity and outcomes. J Clin Child Adolesc Psychol. 2014;43(5):785-795.
  9. Storch EA, et al. Family accommodation in pediatric OCD. J Clin Child Adolesc Psychol. 2007;36(2):207-216.
  10. Calvocoressi L, et al. Family accommodation in OCD: instrument development and assessment. J Nerv Ment Dis. 1999;187(10):636-642.
  11. Russell AJ, et al. Cognitive-behavior therapy for comorbid OCD in high-functioning autism: an RCT. J Child Psychol Psychiatry. 2013;54(7):697-708.
  12. Postlethwaite A, et al. Prevalence of suicidal thoughts and behaviours in OCD: meta-analysis. J Affect Disord. 2019;256:174-187.
  13. Albert U, et al. Suicide risk in OCD and exploration of risk factors: systematic review. Curr Neuropharmacol. 2019;17(8):681-696.
  14. Krzyszkowiak W, et al. Cognitive-behavioural therapy for OCD during pregnancy and postpartum. Psychiatr Pol. 2019;53(2):417-432.
  15. Russell EJ, et al. Risk of perinatal OCD: meta-analysis. J Clin Psychiatry. 2013;74(4):377-385.
  16. Brandes M, et al. Postpartum onset OCD: diagnosis and management. Arch Womens Ment Health. 2004;7(2):99-110.
  17. McGuinness M, et al. The relationship between OCD and stress: cortisol and HPA axis dysregulation. Psychoneuroendocrinology. 2017;82:70-79.
  18. Adams TG, et al. Stress, HPA axis, and OCD severity. Depress Anxiety. 2018;35(8):724-731.
  19. Real E, et al. Stressful life events at onset of OCD: relevance to clinical phenotype. J Affect Disord. 2011;130(3):459-463.
  20. Pinto A, et al. Theme shifting in OCD: clinical characteristics and treatment implications. J Anxiety Disord. 2008;22(8):1499-1505.
  21. Williams MT, et al. Heterogeneity of OCD: subtypes and theme presentations. Curr Psychiatry Rep. 2013;15(11):396.
  22. Mataix-Cols D, et al. Symptom dimensions in OCD: implications for assessment and treatment. J Clin Psychiatry. 2005;66(11):1379-1387.
  23. Hezel DM, McNally RJ. A theoretical review of cognitive biases and deficits in OCD. Biol Psychol. 2016;121:221-232.
  24. Wheaton MG, et al. Relapse prevention in OCD after ERP: predictors and strategies. Cogn Behav Ther. 2018;47(2):149-164.
  25. Simpson HB, et al. Maintenance treatment in OCD: prevention of relapse. Br J Psychiatry. 2010;197(2):128-134.
  26. Fineberg NA, et al. Pharmacotherapy of OCD: evidence-based treatment and beyond. Aust N Z J Psychiatry. 2013;47(2):121-141.
  27. Kotapati VP, et al. Effectiveness of ERP combined with SSRIs in OCD: meta-analysis. Front Psychiatry. 2019;10:150.
  28. McKay D, et al. Efficacy of cognitive-behavioral therapy for OCD: a meta-analysis. Clin Psychol Rev. 2015;40:156-169.
  29. Hofmann SG, et al. The efficacy of cognitive behavioral therapy: a review of meta-analyses. Cognit Ther Res. 2012;36(5):427-440.
  30. Olatunji BO, et al. Cognitive-behavioral therapy for OCD: a meta-analysis of treatment outcome and moderators. J Psychiatr Res. 2013;47(1):33-41.
  31. National Institute of Mental Health (NIMH). Obsessive-Compulsive Disorder. NIMH; 2023.
  32. Mayo Clinic. Obsessive-Compulsive Disorder (OCD): Diagnosis and Treatment. Mayo Foundation; 2024.
  33. Cleveland Clinic. Obsessive-Compulsive Disorder (OCD). Cleveland Clinic Health Library; 2024.
  34. Anxiety and Depression Association of America (ADAA). OCD: Symptoms and Treatment. ADAA; 2024.
  35. World Health Organization (WHO). ICD-11 for Mortality and Morbidity Statistics: 6B20 Obsessive-compulsive disorder. WHO; 2024.

Ready to Get Help for OCD?

Evidence-based treatment with ERP, I-CBT, ACT, and neurofeedback support. In-person in Coquitlam (Greater Vancouver) and online across British Columbia. Service in English and Persian (Farsi).

Visit Home Page All FAQ Pillars

Dr. Samuel — Registered Clinical Counsellor & Neurofeedback Practitioner